Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...
Beam Therapeutics has announced significant progress in its clinical trials and portfolio regarding precision genetic medicines, particularly in the area of sickle cell disease (SCD). Over 40 adult ...
Beam Therapeutics set out to show how the precision of base-editing could produce new genetic medicines addressing a wide range of diseases. That goal may yet be realized, but the company is now ...
Beam Therapeutics is set to present positive and significant data from the BEACON Phase 1/2 clinical trial of BEAM-101 at a major conference, enhancing visibility and credibility within the scientific ...
Beam Therapeutics (NASDAQ:BEAM) shared promising results from the early stage trial of its genetically modified cell therapy, BEAM-101, for the treatment of severe sickle cell disease. The data ...
CAMBRIDGE, Mass., Dec. 06, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced ...
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best CRISPR stocks to buy. On June 13, Beam Therapeutics Inc. (NASDAQ:BEAM) announced new efficacy and safety findings from its BEACON Phase 1/2 ...
The LCL Series thin-beam load cells are designed to measure force or weight. An integrated strain gage includes four active-arm full-bridge, all-balancing compensating and conductive elements.
Step onto any household or commercial weighing scale, and suddenly your weight magically appears in neat digital numbers. But how does a simple platform know exactly how much you weigh down to a tenth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results